| ATPC 0.1158 65.43% | MTEN 0.0332 -5.95% | OCG 0.0099 -16.10% | SOXS 2.0697 -9.22% | AUID 1.9199 93.44% | CJMB 4.03 259.82% | IVP 0.0514 -37.32% | ZSL 2.8799 2.31% | NVDA 189.4801 3.46% | SLV 83.88 -0.80% | SPHL 16.86 649.33% | INTC 49.04 0.66% | ASST 0.9901 -3.87% | DVLT 0.745 3.73% | BNKK 4.175 50.18% | TZA 5.9265 -3.79% | APLT 0.1 0.10% | SOXL 60.8798 9.93% | TQQQ 55.4888 3.08% | BYND 1.0415 8.28% | GRAB 4.37 -5.62% | BBAI 6.4 2.24% | ONDS 13.575 0.11% | IBRX 3.9 29.14% | DUST 5.735 -1.04% | NVD 6.9084 -6.77% | TSLL 18.4101 1.88% | EEM 58.3301 1.00% | TSLS 5.135 -1.06% | BITO 13.315 -1.81% | DNN 3.551 1.75% | AAL 15.735 3.93% | PLUG 2.315 -1.49% | MSTX 4.93 -5.19% | SPY 694.945 0.66% | AMD 236.845 5.92% | JDST 2.075 -1.43% | NOK 6.715 5.58% | IBIT 54.45 -1.79% | RZLV 4.7555 17.13% | FNGD 5.375 -2.45% | SIDU 3.745 -0.13% | XLE 47.815 -0.51% | QQQ 625.95 1.03% | GPUS 0.2932 -8.63% | VALE 14.795 1.27% | TSM 344.39 5.28% | TSLA 443.57 0.99% | ACHR 9.215 3.42% | SQQQ 64.8865 -3.07%

Lazard Ltd (NYSE:LAZ) Surpasses Market Expectations with Strong Financial Performance

Lazard Ltd (NYSE:LAZ) is a prominent financial advisory and asset management firm, competing with giants like Goldman Sachs and Morgan Stanley. On October 23, 2025, Lazard reported earnings that showcased a strong financial performance, exceeding market expectations.

Lazard's Earnings Per Share (EPS) for the third quarter of 2025 was $0.56, surpassing the estimated EPS of $0.44. This represents a significant improvement from the previous year's EPS of $0.38. The company's ability to exceed the consensus EPS estimate of $0.41 by 36.59% highlights its strong performance and potential for future growth, as noted by Zacks.

The company's revenue for the quarter reached $748.08 million, exceeding the estimated $726.25 million. This figure also marks a 12.2% increase from the same period last year, when revenue was $645.91 million. Lazard's consistent ability to outperform revenue estimates, with a positive surprise of 3.85%, underscores its robust financial health.

Lazard's financial metrics provide further insights into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 15.04, indicating how the market values its earnings. Its price-to-sales ratio is about 1.46, reflecting investor willingness to pay per dollar of sales. The enterprise value to sales ratio stands at 1.31, showing its total valuation relative to revenue.

The company's financial stability is also evident in its debt-to-equity ratio of 0.70, indicating a balanced approach to financing its assets. Lazard's current ratio of 1.89 suggests a strong ability to cover short-term liabilities with short-term assets. These metrics, combined with an earnings yield of 6.65%, provide a comprehensive view of Lazard's financial position and potential for investors.

Published on: October 23, 2025